6. Olanzapine in Treatment for Bipolar Disorder

  1. Hagop S. Akiskal1 and
  2. Mauricio Tohen2,3
  1. Mauricio Tohen2,3,
  2. Giedra Campbell3 and
  3. Daniel Lin3

Published Online: 31 MAY 2006

DOI: 10.1002/0470017953.ch6

Bipolar Psychopharmacotherapy: Caring for the Patient

Bipolar Psychopharmacotherapy: Caring for the Patient

How to Cite

Tohen, M., Campbell, G. and Lin, D. (2005) Olanzapine in Treatment for Bipolar Disorder, in Bipolar Psychopharmacotherapy: Caring for the Patient (eds H. S. Akiskal and M. Tohen), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470017953.ch6

Editor Information

  1. 1

    International Mood Center, Department of Psychiatry at the University of San Diego and Veterans Administration Medical Center, 3350 La Jolla Village Dr. (116-A), San Diego, CA 92161, USA

  2. 2

    McLean Hospital, Harvard Medical School, Belmont, MA, USA

  3. 3

    Lilly Research Laboratories, Eli Lilly & Co, 525 S. Meridian Street, Indianapolis, IN 46225, USA

Author Information

  1. 2

    McLean Hospital, Harvard Medical School, Belmont, MA, USA

  2. 3

    Lilly Research Laboratories, Eli Lilly & Co, 525 S. Meridian Street, Indianapolis, IN 46225, USA

Publication History

  1. Published Online: 31 MAY 2006
  2. Published Print: 11 NOV 2005

ISBN Information

Print ISBN: 9780470856079

Online ISBN: 9780470017951

SEARCH

Keywords:

  • extrapyramidal symptoms (EPS);
  • superior antipsychotic efficacy;
  • young mania rating scale (YMRS);
  • olanzapine cotherapy;
  • efficacy in bipolar maintenance;
  • relapse prevention;
  • symptom-rating scale;
  • haloperidol-controlled study

Summary

This chapter contains sections titled:

  • Rationale behind the Clinical Trial Development of Olanzapine

  • Efficacy in the Treatment for Acute Mania

  • Efficacy in the Treatment for Bipolar Depression

  • Efficacy in Bipolar Maintenance/Relapse Prevention

  • Safety and Tolerability

  • Summary

  • References